expression of LATS1 has been found to decrease in sarcomas, astrocytomas and soft tissue origin tumors.26 Recent studies have reported that LATS1 expression decreased in gastrointestinal system cancers but it was overexpressed in CRC.8 Our results indicate that LATS1 gene expression reduced in HT29 CRC cell lines in the administration of 12.5 nM of apigenin after 24 hours and in the administration of 25 and 50 nM of apigenin 48 hours after. This evidence concerns the gene LATS1 and digestive system cancer.